Oncologic and functional outcomes following robot assisted radical prostatectomy: 15-Year experience in a Latin American referral center

IF 2.3 4区 医学 Q3 ONCOLOGY
Agustin Romeo, Pablo Martinez, Martin Compagnucci, Ignacio Tobia, Carlos Giudice, Wenceslao Villamil
{"title":"Oncologic and functional outcomes following robot assisted radical prostatectomy: 15-Year experience in a Latin American referral center","authors":"Agustin Romeo,&nbsp;Pablo Martinez,&nbsp;Martin Compagnucci,&nbsp;Ignacio Tobia,&nbsp;Carlos Giudice,&nbsp;Wenceslao Villamil","doi":"10.1016/j.suronc.2024.102138","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Prostate cancer is the most common cancer in men with more than 52,000 cases diagnosed every year on average. With the introduction of robotic surgery, robotic assisted radical prostatectomy (RARP) has become a popular treatment option in recent years. Achieving oncological control, urinary continence and satisfactory erectile sexual function after RP is the main goal also known as “trifecta”. All these outcomes are highly influenced by surgical experience and caseload. The main objective of this study is to analyze oncological and functional outcomes in RARP after 15 years of experience.</p></div><div><h3>Methods</h3><p>From 2008 until December 2023, 1790 RARP for localized prostate cancer were performed. A retrospective analysis was conducted based on prospectively collected data correlated with electronic medical records.</p></div><div><h3>Results</h3><p>Subgroup analyses were conducted in order to evaluate oncological and functional outcomes (n: 1400). Red blood cell transfusion and conversion to open surgery rate was 1.9 % and 0.1 %, respectively. Mean surgical time was 194 min. Mean follow-up time was 69.5 months, 23.8 % patients experienced biochemical recurrence and 1 % died, primarily due to disease progression. Estimated 10-year recurrence-free survival was 68.7 % (95 % CI 67.2–72.2) while estimated 10-year overall survival was 97.9 % (95 % CI 96.3–99.4). Overall urinary continence rate at 2 years was 86.9 % while satisfactory erectile function rate at 18 months was 56.8 %.</p></div><div><h3>Conclusions</h3><p>Robotic-assisted radical prostatectomy has become a standard surgical technique in our urological practice for the management of clinically localized and locally advanced prostate tumors in selected cases. After 15 years since the inception of our robotic surgery program, we can conclude that our results are comparable to those published in the international literature, enabling patients to maintain satisfactory sexual function with a high continence rate within the first year of surgery.</p></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Surgical Oncology-Oxford","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0960740424001063","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Prostate cancer is the most common cancer in men with more than 52,000 cases diagnosed every year on average. With the introduction of robotic surgery, robotic assisted radical prostatectomy (RARP) has become a popular treatment option in recent years. Achieving oncological control, urinary continence and satisfactory erectile sexual function after RP is the main goal also known as “trifecta”. All these outcomes are highly influenced by surgical experience and caseload. The main objective of this study is to analyze oncological and functional outcomes in RARP after 15 years of experience.

Methods

From 2008 until December 2023, 1790 RARP for localized prostate cancer were performed. A retrospective analysis was conducted based on prospectively collected data correlated with electronic medical records.

Results

Subgroup analyses were conducted in order to evaluate oncological and functional outcomes (n: 1400). Red blood cell transfusion and conversion to open surgery rate was 1.9 % and 0.1 %, respectively. Mean surgical time was 194 min. Mean follow-up time was 69.5 months, 23.8 % patients experienced biochemical recurrence and 1 % died, primarily due to disease progression. Estimated 10-year recurrence-free survival was 68.7 % (95 % CI 67.2–72.2) while estimated 10-year overall survival was 97.9 % (95 % CI 96.3–99.4). Overall urinary continence rate at 2 years was 86.9 % while satisfactory erectile function rate at 18 months was 56.8 %.

Conclusions

Robotic-assisted radical prostatectomy has become a standard surgical technique in our urological practice for the management of clinically localized and locally advanced prostate tumors in selected cases. After 15 years since the inception of our robotic surgery program, we can conclude that our results are comparable to those published in the international literature, enabling patients to maintain satisfactory sexual function with a high continence rate within the first year of surgery.

机器人辅助根治性前列腺切除术后的肿瘤和功能结果:拉丁美洲转诊中心的 15 年经验
背景前列腺癌是男性最常见的癌症,平均每年确诊 52,000 多例。近年来,随着机器人手术的引入,机器人辅助前列腺癌根治术(RARP)已成为一种流行的治疗方法。前列腺癌根治术后达到肿瘤控制、排尿通畅和满意的勃起性功能是主要目标,也被称为 "三连胜"。所有这些结果都受到手术经验和病例数量的很大影响。本研究的主要目的是分析 RARP 术后 15 年的肿瘤学和功能性结果。方法从 2008 年到 2023 年 12 月,共进行了 1790 例局部前列腺癌 RARP 术。结果为了评估肿瘤学和功能性结果,进行了分组分析(n:1400)。输红细胞和转为开放手术的比例分别为 1.9 % 和 0.1 %。平均手术时间为 194 分钟。平均随访时间为69.5个月,23.8%的患者出现生化复发,1%的患者死亡,主要原因是疾病进展。估计10年无复发生存率为68.7%(95% CI为67.2-72.2),估计10年总生存率为97.9%(95% CI为96.3-99.4)。结论机器人辅助前列腺癌根治术已成为我们泌尿外科治疗临床局部和局部晚期前列腺肿瘤的标准手术技术。我们的机器人手术项目开展 15 年后,我们可以得出结论,我们的结果与国际文献中发表的结果相当,使患者在术后第一年内就能保持满意的性功能和较高的尿失禁率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Surgical Oncology-Oxford
Surgical Oncology-Oxford 医学-外科
CiteScore
4.50
自引率
0.00%
发文量
169
审稿时长
38 days
期刊介绍: Surgical Oncology is a peer reviewed journal publishing review articles that contribute to the advancement of knowledge in surgical oncology and related fields of interest. Articles represent a spectrum of current technology in oncology research as well as those concerning clinical trials, surgical technique, methods of investigation and patient evaluation. Surgical Oncology publishes comprehensive Reviews that examine individual topics in considerable detail, in addition to editorials and commentaries which focus on selected papers. The journal also publishes special issues which explore topics of interest to surgical oncologists in great detail - outlining recent advancements and providing readers with the most up to date information.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信